Nov 19 2011
This post in the Center for Global Health Policy's "Science Speaks" blog examines a report (.pdf) by the PEPFAR Scientific Advisory Board (SAB) that offers six recommended treatment and prevention research priorities to U.S. Global AIDS Ambassador Eric Goosby and the Office of the Global AIDS Coordinator (OGAC) to guide future PEPFAR programs. According to the blog, the recommendations grew out of a SAB meeting in September "to discuss the results of the HIV Prevention Trials Network (HPTN) 052 trial, which found that individuals with HIV infection who were given immediate antiretroviral therapy (ART) were 96 percent less likely to transmit the virus to their uninfected sexual partners than those whose treatment was delayed" (Mazzotta, 11/17).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |